CHALLENGE- PATIENT ACCESS TEAM


CHALLENGE

  • An emerging Life Sciences company had a treatment for rare metabolic disease
  • Some patient upon diagnosis were denied access through Medicaid
  • Patient engagement services and HUB vendors were not equipped to negotiate government processes
  • Product moved from managed care to fee-for-service with no instructions for physicians and patients to access medication
  • The physicians were global thought leaders and time was a challenge for their involvement.
  • However, patients suffered setbacks without access to therapy
  • Patient families reluctant to approach local state representative and the Medicaid program
APPROACH – PATIENT ACCESS TEAM


APPROACH

  • Members of the Acuity team were brought into the company as a part of a broader diagnostic of patient engagement.
  • Created a focused State response team integrated with State Government Affairs, Patient Advocacy, Market Access, and Patient Engagement Services.
  • Provided program decision makers with educational information on disease through state based stakeholders such as physicians, local trade organizations and contract lobbyists.
  • Continued to keep in contact with State personnel throughout process.

 

RESULTS – PATIENT ACCESS TEAM


RESULTS

  • State created clear process for requesting coverage, review of applications, and contacts of key personnel involved moving forward.
  • When process finalized, trained HUB on new state processes to ensure ocmpliance and patient access to appropriate care.
  • Internal process expanded to other rare disease therapy to support patient access efforts.

 

Opioids: Use as Directed

Opioids: Use as Directed

By Jeff Oldham & Michael Hamrick December 04, 2018 Source: RealClear Health No one disputes that opioid addiction is a problem in need of varied solutions, as each person struggling is a story all his or her own. The opioid abuse epidemic has been a runaway freight train, barreling out of control through communities and lives, without much…

CHALLENGE – HEMOPHILIA


CHALLENGE

  • Biogen seeking to shift from solely an MS-identified leader in biotech to a trusted leader in hemophilia
  • The hemophilia community is entrenched with longstanding big-pharma corporate partners
  • Hemophilia patients have been burned before and building trust within their community is difficult and takes time
  • Biogen needed to establish trusted relationships with patients, patient organizations and KOLs in short order as they were expecting approval of two novel therapies within the year

 

APPROACH – HEMOPHILIA


APPROACH

  • Aligned with patient community to listen to/uncover unmet needs
  • Proposed a multi-stakeholder collaboration that offered free genotyping at all hemophilia treatment centers (HTCs) throughout US
  • Biogen partnered with the National Hemophilia Foundation, American Thrombosis and Hemostasis Center and Bloodworks NorthWest to offer funding and scientific leadership for My Life, Our Future (MLOF) genotyping initiative.
  • Each partner worked together to raise awareness of MLOF and socialize the offering to the community via social media and educational symposiums throughout the US.
RESULTS – HEMOPHILIA


RESULTS

  • Biogen rapidly gained positive exposure to the hemophilia community demonstrating corporate leadership in a disease state that is difficult to break into.
  • Biogen built trust in a skeptical patient community by identifying itself as a partner providing a solution to an unmet medical need
  • MLOF provided an opportunity to establish a data set that researchers could tap into further R&D for better treatments for bleeding disorders.
  • Beyond building trust and demonstrating leadership, this advocacy initiative resulted in intimate and trustworthy relationships with HCP KOLs and patient leaders within hemophilia – an asset during the commercial launch of the 2 approved products for patients with hemophilia.

 

CHALLENGE – RARE DISEASE


CHALLENGE

  • An emerging Life Sciences company developing a treatment hoped to address an ultra rare, metabolic, genetic disorder
  • This patient community was fragmented without a patient advocacy organization
  • This patient community was fragmented without a patient advocacy organization
  • Company didn’t have anywhere to query patients when seeking input for natural history study, clinical trial design, etc.
APPROACH- RARE DISEASE


APPROACH

  • Company identified a patient leader with demonstrated non-profit leadership experience, poised to lead the creation of this US- based patient advocacy organization as Executive Director.
  • Company provided an unrestricted grant to underwrite the start up costs associated with the groups build out.
  • Company hired consultant to assist the Executive Director with strategic and tactical support, outreaching to centers of excellence to identify diagnosed patients, build a website and other educational tools and establishing a repository for all things related to this condition.
  • Patient Organization garnered additional corporate support to fund the mission and now stands fully functioning as a trusted go to for patients and caregivers once diagnosed with this disease.